Core Viewpoint - Conmed (CNMD) reported a revenue increase of 4.6% year-over-year for Q2 2024, with earnings per share (EPS) also showing improvement compared to the previous year [1] Revenue Performance - Total revenue for the quarter was $332.1 million, slightly below the Zacks Consensus Estimate of $334.56 million, resulting in a revenue surprise of -0.74% [1] - Domestic revenue reached $185.40 million, exceeding the average estimate of $183.93 million, marking a year-over-year increase of 6.1% [3] - International revenue was $146.70 million, falling short of the average estimate of $151.07 million, with a year-over-year increase of 2.6% [4] Segment Performance - Net sales in Orthopedic Surgery were $139.50 million, below the estimated $140.96 million, reflecting a year-over-year decrease of 0.9% [5] - Net sales in General Surgery amounted to $192.60 million, surpassing the average estimate of $189.61 million, with a year-over-year increase of 8.9% [6] - Net sales for Single-use Products were $279.30 million, exceeding the average estimate of $276.53 million, representing a year-over-year increase of 5.5% [7] - Net sales in Capital Products were $52.80 million, below the estimated $58.45 million, showing a year-over-year decrease of 0.2% [8] Stock Performance - Conmed's shares have returned +3.7% over the past month, contrasting with a -0.4% change in the Zacks S&P 500 composite [8] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [8]

Core Viewpoint - Conmed (CNMD) reported quarterly earnings of $0.98 per share, exceeding the Zacks Consensus Estimate of $0.92 per share, and showing an increase from $0.83 per share a year ago, representing an earnings surprise of 6.52% [1] Financial Performance - The company posted revenues of $332.1 million for the quarter ended June 2024, which was below the Zacks Consensus Estimate by 0.74%, compared to $317.65 million in the same quarter last year [2] - Over the last four quarters, Conmed has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Conmed shares have declined approximately 36.5% since the beginning of the year, contrasting with the S&P 500's gain of 14% [3] - The current Zacks Rank for Conmed is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.17 on revenues of $335.32 million, and for the current fiscal year, it is $4.30 on revenues of $1.34 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may change following the recent earnings report [6] Industry Context - The Medical - Dental Supplies industry, to which Conmed belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - The performance of Conmed's stock may also be influenced by the overall outlook for the industry [8]

CONMED Investor Presentation Q2 2024 Earnings Call Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer July 31, 2024 Forward-Looking Information 2 This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forwardlooking statements ...

| --- | --- | --- | --- | |-------|-------|-------|------------------------------------------------| | | | | NEWS RELEASE | | | | | CONTACT : | | | | | CONMED Corporation | | | | | Todd W. Garner Chief Financial Officer | | | | | 727-214-2975 | | | | | ToddGarner@conmed.com | CONMED Corporation Announces Second Quarter 2024 Financial Results Largo, Florida, July 31, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highli ...

Core Viewpoint - The upcoming earnings report for Conmed is anticipated to show a year-over-year increase in earnings and revenues, with the stock's movement largely dependent on the actual results compared to expectations [13]. Earnings Expectations - Conmed is expected to report quarterly earnings of $0.92 per share, reflecting a year-over-year increase of +10.8% [2]. - Revenues are projected to be $334.56 million, which is a 5.3% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their views [4]. - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [9]. Historical Performance - In the last reported quarter, Conmed was expected to post earnings of $0.74 per share but exceeded expectations with earnings of $0.79, resulting in a surprise of +6.76% [11]. - Over the past four quarters, Conmed has beaten consensus EPS estimates three times [19]. Current Stock Rating - Conmed currently holds a Zacks Rank of 4, indicating a "Sell" rating, which complicates the prediction of an earnings beat [10][17].

CONMED Corporation (CNMD) delivered adjusted earnings per share (EPS) of $0.79 in first-quarter 2024, which beat the Zacks Consensus Estimate of $0.74 by 6.8%. The bottom line improved 19.7% from the year-ago quarter’s level.GAAP EPS for the quarter was 63 cents compared with 6 cents per share in the year-ago period.The company’s shares have lost 25.8% in the past six months against the industry’s rise of 10.0%. The broader S&P 500 Index has gained 23% in the same time frame.Image Source: Zacks Investment R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Smaller reporting company ☐ Emerging growth company ☐ The number of ...

Investor Presentation Q1 2024 Earnings Call This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forwardlooking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-lo ...

Call End: CONMED Corporation (NYSE:CNMD) Q1 2024 Earnings Conference Call April 24, 2024, 16:30 PM ET Company Participants Curt Hartman - Chair, President and Chief Executive Officer Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Young Li - Jefferies Vik Chopra - Wells Fargo Kristen Stewart - CL King Rick Wise - Stifel Robbie Marcus - J.P. Morgan Travis Steed - BofA Securities Mike Matson - Needham Operator Thank you for standing ...

For the quarter ended March 2024, Conmed (CNMD) reported revenue of $312.27 million, up 5.7% over the same period last year. EPS came in at $0.79, compared to $0.66 in the year-ago quarter.The reported revenue represents a surprise of +1.70% over the Zacks Consensus Estimate of $307.06 million. With the consensus EPS estimate being $0.74, the EPS surprise was +6.76%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...